Takeaways

#
  • Strazza explicitly allowed for a loss much larger than a planned stop after a biotech news event.
  • He spread exposure across a basket of stocks selected for relative strength and defined chart setups.
  • His expectation that winners could offset losers was a strategy objective, not a guaranteed portfolio outcome.
  • Israel added pipeline research and awareness of upcoming trial results to the preparation for holding a biotech stock.

A well-defined chart entry cannot control when a biotech company releases important news. A trial result or regulatory decision can move the stock through the price at which its owner intended to exit.

A viewer raised that problem on the November 22, 2024 Morning Show, asking how traders could manage positions vulnerable to abrupt moves in either direction. Steve Strazza answered with a hypothetical: a trader might plan to lose 5%, then face a 40% decline after news outside regular trading hours. The planned stop would not make the larger loss disappear.

Build the basket around the risk that remains

Strazza’s approach was to spread exposure among multiple biotechnology stocks. He wanted companies showing relative strength and clearly defined breakout patterns, then managed them as a basket rather than depending on one position.

The technical work still served a purpose. It helped him select the stocks he preferred and identify when their price behavior weakened. But he entered those trades expecting that some could suffer a much larger loss than the chart-based exit had anticipated.

He hoped the strongest positions in a favorable market would generate enough gains to offset failures elsewhere. That was the portfolio outcome he was seeking, not an assurance that the winners would always cover the losers.

At the time, Strazza said he had recently owned close to 20 biotech positions and had been stopped out of six or seven. He was considering buying some back. His account described an actively managed group of positions, with individual exits continuing even while he remained interested in the industry.

Read the event calendar alongside the chart

Spencer Israel added a second part to the preparation: examine the company’s pipeline and know whether a trial readout is approaching. A trader planning to hold for several weeks could otherwise encounter an event they had not considered when opening the position.

Israel mentioned using a biotech catalyst calendar to identify those milestones. The useful information was the event and its timing. Knowing that a result was due would not reveal whether it would be favorable, but it would make the exposure more visible before the announcement.

Keep technical analysis in its proper role

The viewer’s concern was that a large news-driven move could overwhelm technical indicators. Strazza agreed that a planned exit could be overtaken, while pointing out that technical analysis covered more than a single support line or price target.

He also used momentum measures to judge whether a move had become extended, and relative strength to choose among companies. Those tools informed selection and trade management. His example still required planning for a loss beyond the intended stop, including in a stock whose chart had looked strong before the news.

Questions and answers

#

Questions answered in the original 2024-11-22 episode.

Can a stop guarantee that a biotech loss stays at 5%?

No. Strazza’s hypothetical showed how after-hours news could produce a 40% decline despite a planned 5% exit. A price gap can take the stock beyond the intended exit level.

Link to this answer

How did Strazza spread this risk?

He built a basket of biotechnology stocks he considered relative-strength leaders, rather than relying on one company. He still expected individual failures and continued to exit positions whose setups weakened.

Link to this answer

What did Israel suggest checking before holding a biotech stock?

He suggested reviewing its pipeline and the timing of upcoming clinical results. That information can identify an approaching event without predicting its outcome.

Link to this answer

Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .